{
    "nct_id": "NCT06406348",
    "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Single Ascending Dose Trial to Assess the Safety, Tolerability and Pharmacokinetic Effects of ALIA-1758 in Healthy Participants",
    "status": "COMPLETED",
    "last_update_time": "2025-07-15",
    "description_brief": "This is a Phase 1, first in human (FIH), double-blind, placebo-controlled, single ascending dose (SAD) trial to assess the safety, tolerability, and pharmacokinetics (PK) of intravenously (IV) or subcutaneously (SC) injected ALIA-1758 in healthy male and female participants.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted biologic",
    "drug": [
        "ALIA-1758 (an anti\u2011pyroglutamate A\u03b2 monoclonal antibody engineered with a transferrin\u2011receptor BBB\u2011shuttle)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The trial tests ALIA\u20111758, which is an antibody directed at pyroglutamate\u2011modified amyloid\u2011\u03b2 (3pE\u2011A\u03b2) and uses a transferrin\u2011receptor (TfR) blood\u2013brain barrier shuttle \u2014 i.e., a biologic designed to target Alzheimer\u2019s pathology (amyloid). \ue200cite\ue202turn0search2\ue202turn0search5\ue201",
        "Act: Key trial details \u2014 Phase 1, first\u2011in\u2011human, single ascending dose (IV or SC) in healthy participants (NCT06406348); lead sponsor Aliada (now acquired by AbbVie). The trial evaluates safety, tolerability, and PK and includes placebo control. \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Mechanism / intent: Preclinical and company descriptions state ALIA\u20111758 is intended to enter brain via TfR-mediated transport and promote degradation/elimination of A\u03b2 (disease\u2011modifying intent rather than symptomatic cognitive enhancement). \ue200cite\ue202turn0search5\ue202turn0search2\ue201",
        "Reflect: Classification check \u2014 given ALIA\u20111758 is a monoclonal antibody targeting amyloid pathology and using a biologic BBB\u2011shuttle, it fits the definition of a 'disease\u2011targeted biologic' (not a small molecule, cognitive enhancer, or symptomatic neuropsychiatric treatment). No substantive ambiguity in available descriptions. \ue200cite\ue202turn0news13\ue201",
        "Web search results used (summary of sources consulted): 1) Clinical trial record/details for NCT06406348 (trial description and design). \ue200cite\ue202turn0search0\ue201 2) MedPath / trial listing with sponsor and timeline details. \ue200cite\ue202turn0search1\ue201 3) ALZFORUM summary describing antibody design and mechanism. \ue200cite\ue202turn0search2\ue201 4) BiopharmaBoardroom summary of Aliada MODEL\u2122 platform and ALIA\u20111758 TfR shuttle / 3pE\u2011A\u03b2 targeting. \ue200cite\ue202turn0search5\ue201 5) News coverage (Reuters/WSJ) reporting AbbVie acquisition and describing ALIA\u20111758 as anti\u2011pyroglutamate A\u03b2 antibody in Phase 1. \ue200cite\ue202turn0news13\ue202turn0news12\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: ALIA-1758 is a monoclonal antibody directed at pyroglutamate\u2011modified amyloid\u2011\u03b2 (3pE\u2011A\u03b2) and is engineered with a transferrin\u2011receptor (TfR) BBB shuttle to enter the brain and promote degradation/elimination of A\u03b2 \u2014 the intervention clearly targets amyloid pathology. \ue200cite\ue202turn0search1\ue202turn0search5\ue201",
        "Act: Key trial details extracted: ALIA\u20111758 (anti\u20113pE\u2011A\u03b2 mAb with TfR BBB shuttle); Phase 1, randomized, double\u2011blind, placebo\u2011controlled, single ascending dose in healthy participants (NCT06406348). These descriptions and the clinical\u2011trial listing identify the drug\u2019s biological target as amyloid\u2011\u03b2. \ue200cite\ue202turn1search6\ue202turn1search0\ue201",
        "Reflect: Classification check \u2014 this is a disease\u2011targeted biologic aimed at removing/modifying amyloid\u2011\u03b2 species (not a symptomatic neurotransmitter agent, inflammation/immune\u2011only modulator, or a diagnostic). There is no indication of multiple distinct CADRO targets, so the most specific CADRO category is A) Amyloid beta. \ue200cite\ue202turn0search6\ue202turn0search2\ue201",
        "Web search results consulted (selected sources): 1) ALZFORUM summary of ALIA\u20111758 (mechanism, TfR shuttle, anti\u20113pE\u2011A\u03b2). \ue200cite\ue202turn0search1\ue201 2) AbbVie / PR news releases describing ALIA\u20111758 as an anti\u2011pyroglutamate A\u03b2 antibody using a BBB\u2011crossing platform. \ue200cite\ue202turn0search5\ue202turn1search1\ue201 3) Industry coverage (BiopharmaBoardroom / Reuters) and company press on the MODEL\u2122 TfR BBB shuttle and acquisition details. \ue200cite\ue202turn0search2\ue202turn0news12\ue201 4) Clinical trial registry entries for NCT06406348 confirming Phase 1 SAD design in healthy participants. \ue200cite\ue202turn1search6\ue202turn1search0\ue201"
    ]
}